The European Cancer Congress 2015

login
My congress planner
close
Forgot password

Create account

Searchable Programme for ECC2015

Keyword / Author:
  • 27
    SUN
    11:30 – 12:30
    Abstract nr
    Melanoma and Skin Cancer

    Proffered Paper Session: Melanoma and Skin Cancer I

    Chair: A. Eggermont (France)

    Chair: C. Robert (France)

    11:30
    22LBA
    LATE BREAKING ABSTRACT: Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma
    Speaker: P. Nghiem (USA)
    Display abstract

    11:40
    23LBA
    LATE BREAKING ABSTRACT: An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)
    Speaker: F.S. Hodi (USA)
    Display abstract

    11:50
    Discussant : C. Robert (France)

    12:00
    24LBA
    LATE BREAKING ABSTRACT: Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma
    Speaker: G. Long (Australia)
    Display abstract

    12:10
    25LBA
    LATE BREAKING ABSTRACT: Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study
    Speaker: G. McArthur (Australia)
    Display abstract

    12:20
    Discussant : D. Schadendorf (Germany)

  • 28
    MON
    08:00 – 08:45
    Melanoma and Skin Cancer

    Teaching Lecture: Immunotherapy in Melanoma: From Frustration to Enthusiasm

    Chair: P.A. Ascierto (Italy)

    Speaker: J. Becker (Austria)
    Display Presentation Details

  • 28
    MON
    09:00 – 10:50
    Abstract nr
    Melanoma and Skin Cancer

    Proffered Paper Session: Melanoma and Skin Cancer II

    Chair: P.A. Ascierto (Italy)

    Chair: H. Gogas (Greece)

    09:00
    3300
    A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma
    Speaker: C. van Herpen (Netherlands)
    Display abstract

    09:15
    3301
    Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
    Speaker: C. Robert (France)
    Display abstract

    09:30
    Discussant : C. Blank (Netherlands)

    09:40
    3302
    Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma
    Speaker: E. Liniker (Australia)
    Display abstract

    09:55
    3303
    Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
    Speaker: J. Larkin (United Kingdom)
    Display abstract

    10:10
    3304
    Metabolic activity in metastatic melanoma after long-term treatment with anti-PD-1 antibodies
    Speaker: B. Kong (Australia)
    Display abstract

    10:25
    3305
    PD1 inhibition-induced changes in melanoma and its associated immune infiltrate
    Speaker: R. Vilain (Australia)
    Display abstract

    10:40
    Discussant : R. Dummer (Switzerland)

  • 28
    MON
    11:30 – 12:30
    Melanoma and Skin Cancer

    Special Session: Biomarkers in Melanoma

    Chair: H. Gogas (Greece)

    11:30
    Immunotherapy: Are there any predictive biomarkers?
    Speaker: A. Marabelle (France)

    11:40
    ECCO-EJC Young Investigator’s Award Winner: The role of circulating tumour cells in melanoma
    Speaker: M.R. Girotti (United Kingdom)

    11:50
    cfDNA
    Speaker: S. El Messaoudi (France)
    Display Presentation Details

    Discussion

  • 28
    MON
    17:00 – 18:30
    Melanoma and Skin Cancer

    Scientific Symposium: Mechanisms of Resistance to Targeted Therapies

    Chair: R. Marais (United Kingdom)

    Co-Chair: D. Schadendorf (Germany)

    17:00
    BRAF signalling in melanoma
    Speaker: R. Marais (United Kingdom)

    17:20
    Signalling networks and resistance
    Speaker: R. Dummer (Switzerland)
    Display Presentation Details

    17:40
    Metabolism and resistance
    Speaker: D. Peeper (Netherlands)

    18:00
    Mechanisms and resistance
    Speaker: G. Long (Australia)
    Display Presentation Details

    Discussion & Roundup

Print all results list